%0 Journal Article %T Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network %+ CIC - Biotherapie - AP-HP (cochin - Pasteur) %+ Hôpital Saint Eloi (CHRU Montpellier) %+ CIC Montpellier %+ Biocommunication en Cardio-Métabolique (BC2M) %A Rondy, M. %A Castilla, J. %A Launay, O. %A Costanzo, S. %A Ezpeleta, C. %A Galtier, F. %A Gaetano Donati, K., De %< avec comité de lecture %@ 2164-5515 %J Human Vaccines & Immunotherapeutics %I Taylor & Francis %V 12 %N 5 %P 1217--1224 %8 2016-02-02 %D 2016 %R 10.1080/21645515.2015.1126013 %M 27065000 %K Influenza vaccine %K multicentre studies %K hospital %K case control studies %K Influenza %Z Life Sciences [q-bio]Journal articles %X We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups. © 2016 Taylor & Francis. %G English %L hal-01380416 %U https://univ-rennes.hal.science/hal-01380416 %~ APHP %~ U835 %~ CIC %~ STATS-UR1 %~ UR1-UFR-SVE %~ UR1-SDV %~ BS %~ UNIV-MONTPELLIER %~ TEST-UNIV-RENNES %~ UNIV-RENNES %~ BC2M %~ UR1-BIO-SA %~ UM-2015-2021